Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Amgen (AMGN) has been heavily searched on Zacks.com, with shares returning -4% over the past month compared to the S&P 500's +5.2% change. Current consensus estimates project a +4.8% year-over-year EPS increase for the current quarter to $5.21, and revenue is expected to grow by 5.6% to $8.86 billion; Amgen's Zacks Rank #3 suggests near-term performance in line with the broader market, while a Value Style Score of B indicates the stock may be trading at a discount to peers.

Analysis

Amgen (AMGN) has attracted significant investor interest recently, despite its shares declining by 4% over the past month, a period during which the S&P 500 composite gained 5.2% and the Zacks Medical - Biomedical and Genetics industry saw a minor loss of 0.6%. The company demonstrated strong financial performance in its last reported quarter, with revenues of $8.15 billion, a 9.4% year-over-year increase, and an EPS of $4.90, surpassing consensus estimates by 2.47% and 17.79% respectively. Amgen has a consistent record of beating EPS estimates over the trailing four quarters. For the current quarter, analysts forecast earnings of $5.21 per share, representing a 4.8% year-over-year growth, although this consensus estimate has been revised downwards by 1.6% in the last 30 days. Current fiscal year EPS is projected at $20.82 (+4.9% YoY), an estimate that has risen 1.2% recently, while next fiscal year's EPS is expected to be $21.26 (+2.1% YoY), with a +0.6% revision in the past month. Revenue growth is also anticipated, with current quarter sales estimated at $8.86 billion (+5.6% YoY), and full-year revenues projected at $35.22 billion (+5.4% YoY) for the current fiscal year and $35.78 billion (+1.6% YoY) for the next. Despite these positive growth indicators and a Zacks Value Style Score of B suggesting the stock is trading at a discount, Amgen carries a Zacks Rank #3 (Hold), implying its near-term performance is expected to align with the broader market.

Key Decisions for Investors

• Investors should evaluate Amgen's attractive valuation, as indicated by its Zacks Value Style Score of B, against its recent share price underperformance and the mixed signals from earnings estimate revisions.
• Closely monitor the upcoming earnings release for validation of the projected 4.8% EPS growth for the current quarter, particularly given the recent -1.6% downward revision in consensus estimates and the stock's Zacks Rank #3 (Hold).
• Consider the projected moderation in revenue and EPS growth for the next fiscal year (+1.6% and +2.1% respectively) when assessing long-term holdings, weighing it against the company's established biotech leadership and historical earnings consistency.